An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).

Shun LuYing ChengJianying ZhouMengzhao WangJun ZhaoBaocheng WangGongyan ChenJifeng FengZhiyong MaLin WuChang-Li WangKewei MaShucai ZhangJun LiangYong SongJie WangYi-Long WuAng LiYizhi HuangJianhua Chang

Published in: Therapeutic advances in medical oncology (2022)

, or PD-L1 status.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
open label
combination therapy
randomized controlled trial